RE: Prevail27 Sep 2023 07:44
Exactly. They will be looking at their 6p a share becoming 60p a share:
* As fund managers, our strategy applies Prevail's expertise in the drug development and monetization process to evaluate and select investment opportunities, equip the process of value creation through successful clinical studies, and drive the realization of that value in a timely and cost-effective way.
* To help promising life sciences companies improve clinical development norms, structure advantageous deals and secure partnering arrangements.
* Prevail Partners invests in firms whom we are confident have bright prospects for growth and faster, surer, higher returns through the execution of their risk-managed and accelerated clinical trials.
* Prevail Partners is an investment fund focused on life sciences companies. The fund is designed to take advantage of, at very favorable terms, the attractive returns possible in promising scientific advances in the fields of healthcare therapies, preventive treatments, medical devices and diagnostics.
* A uniquely favorable feature of the fund is that Prevail InfoWorks applies proprietary technologies to equip companies in which the fund invests, giving investors comfort that the trials have a high likelihood of success.
Case History;
United Therapuetics LungRx TRIUMPH-1 trial.
“With Prevail, we launched this trial on time, after a very short start-up period,” LungRx press release
“We believe that the Prevail system which UTHR has employed for TRIUMPH-1 will allow for more rapid turnaround in data,” C.E. Unterberg, Towbin analyst report.
United Therapeutics’ market value jumped about $300 million based on the reported results.
Prevail will be looking for the same with HEMO. i.e. they will be expecting "attractive returns", which in in plain English equates to many multiples higher than their investment....
Good luck, Brighty
Sign In
Follow the stocks
